Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
=== Burial at crossroads === Historically, crossroad graves were used to dispose of the bodies of executed criminals and suicides. They were located at a crossroads, often on a parish border. In Great Britain, until the Burial of Suicides Act 1823, suicides were generally not allowed a burial in consecrated ground, and the burial far outside the community, sometimes with a stake through their heart, was seen as a way to keep their spirits from haunting the area. Crossroads form a crude cross shape and this may have given rise to the belief that these spots were selected as burying-places which were next best to consecrated ground. The shape was seen as a powerful symbol against all kinds of unwelcome powers. Another possible explanation is that the ancient Teutonic (Germanic) ethnic groups often built their altars at a crossroads, and since human sacrifices, especially of criminals, formed part of ritual, these spots came to be regarded as execution grounds. Hence after the introduction of Christianity, criminals and suicides were buried at the crossroads during the night, to assimilate as far as possible their funeral with that of the pagans. An example of a crossroad execution-ground was the famous Tyburn in London, which stood on the spot where the Roman road to Edgware and beyond met the Roman road heading west out of London. Superstition also played a part in the selection of crossroads in the burial of suicides.
=== Cold Fusion 3 === Version 3, released in June 1997, brought custom tags, cfsearch/cfindex/cfcollection based on the Verity search engine, the server scope, and template encoding (called then "encryption"). Version 3.1, released in Jan 1998, added RDS support as well as a port to the Sun Solaris operating system, while ColdFusion studio gained a live page preview and HTML syntax checker.
Molecular glues that target BRD4 for degradation, lead to 26S proteasome generated peptides that release Inhibitor of apoptosis (IAPs) leading to Apoptosis, suggesting that the peptides generated by the 26S act as secondary metabolites that drive major cell processes.
Sources: en.wikipedia.org
The National Dope Testing Laboratory (NDTL) is a premier analytical testing & research organization established as an autonomous body under the Ministry of Youth Affairs and Sports, Government of India. It is the only laboratory in the country responsible for human sports dope testing. It is headed by Chief Executive Officer (CEO). Dr. Puran Lal Sahu is the Scientific Director of NDTL. It is accredited by National Accreditation Board for Testing & Calibration Laboratories, NABL (ISO/IEC 17025:2017) for human dope testing of urine & blood samples from human sports. NDTL is one of the 29 WADA accredited laboratories Archived 2021-04-18 at the Wayback Machine in the world. It is one of the modern and state-of-the-art laboratories in the country equipped with the latest analytical instrumentation.
=== The Lancet COVID-19 Commission task force === In November 2020, Richard Horton, editor of The Lancet, appointed economist Jeffrey Sachs as chair of its COVID-19 Commission, with wide-ranging goals relating to the virus and pandemic. Sachs set up a number of task forces, including one on the origins of the virus. Sachs appointed Peter Daszak, a colleague of Sachs' at Columbia, to head this task force, two weeks after the Trump administration prematurely ended a federal grant supporting a project led by Daszak, EcoHealth Alliance, which worked with the Wuhan Institute of Virology. This appointment was criticised as creating a conflict of interest, for instance by Richard Ebright, chemical biologist at Rutgers University, who called the commission an "entirely Potemkin commission" in the National Review. Daszak stated that the task force was formed to "conduct a thorough and rigorous investigation into the origins and early spread of SARS-CoV-2". The task force has twelve members with backgrounds in One Health, outbreak investigation, virology, lab biosecurity and disease ecology. The task force planned to analyse scientific findings and did not plan to visit China. However, as Sachs became increasingly drawn to the lab leak theory, he came into conflict with Daszak and his task force. In June 2021, The Lancet announced that Daszak had recused himself from the commission. On 25 September 2021, the task force work was folded after procedural concerns and a need to broaden its scope to examine transparency and government regulation of risky laboratory research.
== Chemistry == Tofu is made from soy milk which is a turbid colloid liquid/solution. Tofu structure is related to soy milk components, particularly colloid components such as protein particles and oil globules. Protein particle content increases with the increase of the globulin ratio in the soybeans. Tofu varieties ensue from adding coagulants at various concentrations.
== Structure and properties == The molecular weight of lactate racemase differs in the various organisms in which it has been found, ranging from 25,000 to 82,400 g/mol. The structure of the enzyme from L. plantarum was solved by Jian Hu and Robert P. Hausinger of Michigan State University and co-workers there and elsewhere. The protein contains a previously unknown covalently-linked nickel-pincer nucleotide (NPN) cofactor (pyridinium 3-thioamide-5-thiocarboxylic acid mononucleotide), where the nickel atom is bound to C4 of the pyridinium ring and two sulfur atoms. This cofactor participates in a proton-coupled hydride-transfer mechanism. There have been a number of recent studies on NPN cofactor synthesis by the LarB, LarE, and LarC proteins. LarB is a carboxylase/hydrolase of nicotinamide adenine dinucleotide (NAD), providing pyridinium-3,5-dicarboxylic acid mononucleotide and adenosine monophosphate (AMP). LarE is an ATP-dependent sulfur transferase that converts the two substrate carboxyl groups into thioacids by sacrificing the sulfur atoms of a cysteine residue in the protein. Finally, LarC inserts nickel into the organic ligand by a CTP-dependent process to complete synthesis of the NPN cofactor.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.